*Optimal dilutions/concentrations should be determined by the researcher.
|2.5 μg/1 × 10⁶ cells
Not tested in other applications.
Recognizes human DC-SIGN on transfected cells and on monocyte derived dentritic cells. The antibody does not react with either parental mouse cells or irrelevant transfectants, such as human DC-SIGN2.
PBS, 5% Trehalose
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Batch dependent (Please refer to the vial label for the specific concentration.)
purified from NIH/3T3 cells transfected with recombinant human DC-SIGN.
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
CD209 molecule , CDSIGN , CLEC4L , DC-SIGN , DC-SIGN1
Dendritic cells (DCs) that control immune responses were recently found to capture and transport HIV from the mucosal area to remote lymph nodes, where DCs hand over HIV to CD4+ T lymphocytes. DCs also amplify the amount of virus and extend the duration of viral infectivity. Multiple strains of HIV1, HIV2 and SIV bind to DCs via DCSIGN. ICAM3 is the natural ligand for DC-SIGN. A DC-SIGN homologue (termed DC-SIGNR, L-SIGN, and DCSIGN2) was identified recently. DC-SIGN forms a novel gene family with DC-SIGNR and many alternatively spliced isoforms of DC-SIGN and DC-SIGNR. The expression of DC-SIGN was found in mucosal tissues including placenta, small intestine, and rectum.